Interdisziplinäre Forschung für innovative Therapien
Neuigkeiten und Termine
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
Besuchen Sie gerne auch unsere Seite auf X und folgen Sie uns, um keine Neuigkeiten aus diesem spannenden Forschungsfeld zu verpassen.
Really great paper by @Markuseckstein3 & Team! Congrats 💪🏼
— Niklas Klümper (@niklas_kluemper) December 30, 2024
AI can guide pre-selection for FGFR3 testing. This has the potential to more broadly assess druggable FGFR alteration in UC ! Especially in settings where FGFR testing is rarely performed..@urotoday @NatureComms… https://t.co/4WSSA3aDtd
🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like!@urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen https://t.co/jC1aEhztgI
— Markus Eckstein (@Markuseckstein3) February 15, 2024
Kooperationspartner
